This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Amitriptylinoxide is a tricyclic antidepressant indicated in the treatment of depressive disorders.
- Generic Name
- Amitriptylinoxide
- DrugBank Accession Number
- DB13114
- Background
Amitriptylinoxide has been used in trials studying Major Depression.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Amitriptylinoxide (DB13114)
- Weight
- Average: 293.41
Monoisotopic: 293.177964365 - Chemical Formula
- C20H23NO
- Synonyms
- Amitriptylinoxide
- External IDs
- J9.621K
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Depressive disorders •••••••••••• •••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of CNS depression can be increased when 1,2-Benzodiazepine is combined with Amitriptylinoxide. Acarbose Amitriptylinoxide may decrease the hypoglycemic activities of Acarbose. Acebutolol Amitriptylinoxide may decrease the antihypertensive activities of Acebutolol. Aceclofenac The risk or severity of gastrointestinal bleeding can be increased when Amitriptylinoxide is combined with Aceclofenac. Acemetacin The risk or severity of gastrointestinal bleeding can be increased when Amitriptylinoxide is combined with Acemetacin. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
Categories
- Drug Categories
- Agents that produce hypertension
- Agents that reduce seizure threshold
- Antidepressive Agents
- Antidepressive Agents, Tricyclic
- Benzocycloheptenes
- Central Nervous System Depressants
- Dibenzocycloheptenes
- Narrow Therapeutic Index Drugs
- Neurotoxic agents
- Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as dibenzocycloheptenes. These are compounds containing a dibenzocycloheptene moiety, which consists of two benzene rings connected by a cycloheptene ring.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Dibenzocycloheptenes
- Sub Class
- Not Available
- Direct Parent
- Dibenzocycloheptenes
- Alternative Parents
- Trialkyl amine oxides / Trisubstituted amine oxides and derivatives / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives
- Substituents
- Aromatic homopolycyclic compound / Dibenzocycloheptene / Hydrocarbon derivative / N-oxide / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organonitrogen compound / Organopnictogen compound / Trialkyl amine oxide
- Molecular Framework
- Aromatic homopolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- TYR2U59WMA
- CAS number
- 4317-14-0
- InChI Key
- ZPMKQFOGINQDAM-UHFFFAOYSA-N
- InChI
- InChI=1S/C20H23NO/c1-21(2,22)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-12H,7,13-15H2,1-2H3
- IUPAC Name
- N,N-dimethyl-3-{tricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3,5,7,11,13-hexaen-2-ylidene}propanamine oxide
- SMILES
- CN(C)(=O)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12
References
- General References
- DIMDI Drug Product Information: Amioxid-Neuraxpharm (amitriptylinoxide) oral tablets [Link]
- External Links
- PubChem Compound
- 20313
- PubChem Substance
- 347829237
- ChemSpider
- 19137
- BindingDB
- 112778
- ChEBI
- 135224
- ChEMBL
- CHEMBL627
- ZINC
- ZINC000001481969
- Wikipedia
- Amitriptylinoxide
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Unknown Status Not Available Major Depressive Disorder (MDD) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet Oral 120 MG Tablet Oral 30 MG Tablet Oral 60 MG Tablet Oral 90 MG - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.000277 mg/mL ALOGPS logP 1.79 ALOGPS logP 3.69 Chemaxon logS -6 ALOGPS pKa (Strongest Basic) 4.04 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 1 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 26.88 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 103.55 m3·mol-1 Chemaxon Polarizability 33.85 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-02u0-2090000000-d7fb06224fe8427373e9 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 186.1207084 predictedDarkChem Lite v0.1.0 [M-H]- 161.87862 predictedDeepCCS 1.0 (2019) [M+H]+ 186.8367084 predictedDarkChem Lite v0.1.0 [M+H]+ 164.2366 predictedDeepCCS 1.0 (2019) [M+Na]+ 186.1058084 predictedDarkChem Lite v0.1.0 [M+Na]+ 170.32976 predictedDeepCCS 1.0 (2019)
Drug created at October 21, 2016 03:19 / Updated at June 12, 2021 10:55